title: [Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].
authors.affiliation: Centre Eugène Marquis, Rennes.
authors.forename: Patrick
authors.initials: P
authors.lastname: Bourguet
authors.forename: François
authors.initials: F
authors.lastname: Planchamp
authors.forename: Jacques
authors.initials: J
authors.lastname: Monteil
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Metges
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Nicole
authors.initials: N
authors.lastname: Tubiana-Mathieu
mesh_terms: D001005:Anus Neoplasms / Q000000981:diagnostic imaging; D001650:Bile Duct Neoplasms / Q000000981:diagnostic imaging; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging; D004067:Digestive System Neoplasms / Q000000981:diagnostic imaging*; D004701:Endocrine Gland Neoplasms / Q000000981:diagnostic imaging; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D007420:Intestine, Large / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000000981:diagnostic imaging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000592:standards*; D019275:Radiopharmaceuticals; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18